NCT04173650 - MSC EVs in Dystrophic Epidermolysis Bullosa | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

March 31, 2026

Conditions

Dystrophic Epidermolysis Bullosa

Interventions

DRUG

AGLE-102

Extracellular vesicles from bone marrow derived mesenchymal stem cells - up to six topical administrations

Trial Locations (3)

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

RECRUITING

Phoenix Children's Hospital, Phoenix

RECRUITING

USC /Norris Comprehensive Cancer Center University of Southern California, Los Angeles